RxDoctor Payments Data

Steve Reeves, MD

General Practice · Hemingway, SCNPI 1750673943

Payments from drug & device makers

$535in general payments, 2019–2025

Across 24 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$145
  • Sanofi-aventis U.S. LLC$96
  • Genentech USA, Inc.$45
  • Lilly USA, LLC$41
  • Novo Nordisk$40
  • Abbott$39
  • plus $130 from 7 others

What the payments were for

  • Food & beverage$52999%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$535 in reported general payments places this provider in the 65th percentile of 1,367 general practice providers in South Carolina.

See all general practice providers in South Carolina

Medicare billing

Part B allowed, 2024
$479
Medicare patients
11
Services billed
13

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tresiba Flextouch U-200Insulin Degludec24$32,585
JanuviaSitagliptin Phosphate15$22,551
OzempicSemaglutide14$15,104
EliquisApixaban13$13,697
Amlodipine Besylate117$671
Albuterol Sulfate HfaAlbuterol Sulfate16$617
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide51$601
Rosuvastatin Calcium35$568
Atorvastatin Calcium79$555
Esomeprazole Magnesium16$545
Omeprazole35$532
Potassium Chloride39$532
Hydralazine Hcl17$443
Diclofenac Sodium17$388
Methylprednisolone38$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$11$22,55115 claims
Novo NordiskOzempic$40$15,10414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,367 general practice providers in South Carolina.

Other general practice in Hemingway

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →